EZH2 and neoplasm: The genetic and epigenetic landscape of these tumor varies widely and the lack of drugs targeting the most common mutated genes (KRAS, TP53, CDKN2A, SMAD4) made the authors to select two epigenetic drugs A366 (inhibitors of G9a) and UNC1999 (EZH2 inhibitor) to be used alone or in combination with gemcitabine, the standard-of-care treatment for this tumor.